Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,276.00
(
0.60%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
100.66
(
0.00%
)
Bitcoin
73,987.72
(
0.06%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 88803

Sunday, 01/10/2010 8:12:31 PM

Sunday, January 10, 2010 8:12:31 PM

Post# of 257253
Two additional changes in VRTX’s guidance from today’s PR:

4. Evidently, there is no longer any plan to disclose the top-line results of the VX-222 phase-1b monotherapy study prior to presentation of the full dataset at an unspecified medical conference in 2010. Previously, VRTX had promised to report the top-line data in 4Q09.

5. There is no plan to report the results of a Telaprvir/VX-222 drug-drug-interaction study. Previously, VRTX had said that these data might be reported to investors.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now